# Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
Canonical URL: https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum-ef62dbcf
Ticker: AVTX
Company: Avalo Therapeutics
Source: Avalo Therapeutics
Published: 2026-07-07 11:00 EST
Original Source URL: https://ir.avalotx.com/news-events-presentations/press-releases/detail/228/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum
## Summary

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated…...

## Article Body
July 07, 2026 7:00am EDT

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com .

For media and investor inquiries

Christopher Sullivan, CFO Avalo Therapeutics, Inc. ir@avalotx.com 410-803-6793

or

Meru Advisors Lauren Glaser lglaser@meruadvisors.com

Source: Avalo Therapeutics Released July 7, 2026
## Recent Company News
- 2026-07-07 11:00 EST — [Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum-ef62dbcf) — Source: Avalo Therapeutics
- 2026-06-26 11:00 EST — [Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes-3ee6d18b) — Source: Avalo Therapeutics
- 2026-06-25 13:46 EST — [Avalo Therapeutics Appoints Ron Philip to Board of Directors](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-appoints-ron-philip-to-board-of-directors) — Source: Avalo Therapeutics
- 2026-06-25 13:46 EST — [Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-expands-pipeline-with-avtx-010-a-long-acting-next-generation-anti-il-1-antibody) — Source: Avalo Therapeutics
- 2026-06-25 13:46 EST — [Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4) — Source: Avalo Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)